2018/6/25 – CRI Report

Global Creatinine Test Market Research Report – Forecast to 2023

admin — Tue, 04 Dec 2018 07:30:43 +0000

Introduction
Creatinine test is a type of blood test that measures the level of creatinine in the blood. When creatine, an amino acid found in the muscle, breaks down, it forms a waste product known as creatinine. It is a waste product that the kidneys normally eliminate from the body. Creatinine levels in the blood help to determine if the kidneys are working well. The growing prevalence of chronic kidney diseases, technological advancements in the kidney function testing, and initiatives taken by the government to control chronic kidney diseases are expected to drive market growth. According to a study published by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) in December 2016, the overall prevalence of chronic kidney diseases (CKD) in the US was approximately 14%. However, false estimates of creatinine tests may hamper the growth of the market.
The global creatinine test market is expected to reach a market value of USD 604.55 million by 2023 from USD 407.41 million in 2016 and is expected to register a CAGR of 5.8% during the forecast period from 2017 to 2023. In 2016, the Americas held the highest share of the market at 35.4%, followed by Europe and Asia-Pacific with shares of 31.4% and 20.5%, respectively. The increasing prevalence of kidney diseases worldwide is expected to increase the growth of the market during the forecast period.
The global creatinine test market is segmented into test type, product type, application, end user, and region.
The global creatinine test market, by test type, is segmented into blood test, urine test, and creatinine clearance test.
The global creatinine test market, by product type, is segmented into consumables and instruments.
The global creatinine test market, by application, is segmented into urinary tract obstruction, renal failure, kidney cancer, and glomerulonephritis.
By end user, the global creatinine test market is segmented into hospitals and clinics, diagnostic centers, and research institutes.
The global creatinine test market is expected to have a value of USD 604.55 million by 2023 from USD 407.41 million in 2017 and is expected to register a CAGR of 5.8% during the forecast period from 2017 to 2023.
Key Players
Siemens AG, Abbott, Thermo Fisher Scientific Inc, Abcam plc, F. Hoffmann-La Roche AG, Nova Biomedical, ACON Laboratories, Inc., OPTI Medical Systems, URIT Medical, Quest Diagnostics, ARKRAY, Inc., and Danaher
Study objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the creatinine test market
• To provide insights into factors affecting the market growth
• To analyze the global creatinine test market based on various tools such as supply chain analysis and Porter’s five force analysis
• To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries
• To provide the country-level analysis of the market with respect to the current market size and future perspective
• To provide country-level analysis of the market for segments by test type, product type, application, end user, and region
• To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market
• To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the creatinine test market
Target Audience
• Diagnostic Centers
• Research and Development (R&D) Companies
• Government Research Institutes
• Academic Institutes and Universities
Key Findings
• The global creatinine test market is expected to reach USD 604.55 million by 2023 at a CAGR of 5.8 % from 2017 to 2023
• On the basis of test type, blood tests are expected to account for the largest market share at a CAGR of 5.32% by 2023
• On the basis of product type, consumables are expected to account for the largest market share at a CAGR of 5.59% by 2023
• On the basis of application, urinary tract obstruction is expected to account for the largest market share at a CAGR of 5.10% by 2023
• On the basis of end user, hospitals and clinics are expected to account for the largest market share at a CAGR of 5.30% by 2023
• The Americas is expected to hold the largest share of the global creatinine test market at a CAGR of 5.91% by 2023
• Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 6.33% by 2023
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o India
o Australia
o Republic of Korea
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

The post Global Creatinine Test Market Research Report – Forecast to 2023 first appeared on CRI Report.

Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022

admin — Fri, 17 Aug 2018 09:05:10 +0000

There are more than 400,000 people with hemophilia in the world, Chinese surpassing 100,000. The registered hemophilia patients in China are less than 20,000, because most patients give up treatment due to the expensive medical expenses. Those who lack coagulation factor VIII account for 80% to 85% of the hemophilia A patients. Currently, there is no cure for hemophilia, treatment for which on the market are all alternatives. Coagulation factors are the main drugs.
In 1992, Baxter (Baxalta) publicized the first recombinant coagulation factor VIII. Because it has the same effects as natural coagulation factors without risks of blood-borne virus contamination, it is very popular in the market. The developed countries master mature technologies of recombinant coagulation factors. For example, recombinant coagulation factor VIII now has experienced four rounds of upgradation. The main manufacturers are Bayer, Baxalta, Wyeth, etc. By Jun. 2018, no domestic recombinant coagulation factor VIII has been launched. In May 2018, China’s local biopharmaceutical company Beijing Tiantan Biological Products Co., Ltd. announced that its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. had received Approval Document for Clinical Trials of recombinant human coagulation factor VIII for injection issued by the CFDA.
Recombinant human coagulation factor VIII developed rapidly after entering China. Its annual sales increased from less than CNY 6 million in 2009 to CNY 300 million in 2017, and the CAGR reached 65.2% from 2009 to 2017. Currently, recombinant human coagulation factor VIII sold on the Chinese market is all imported from Bayer, Baxalta and Wyeth. Bayer secures the highest market share, which was close to 68% in 2017.
CRI forecasts that with the development of China’s economy, patients with hemophilia are more able to pay medical expenses. It is expected that the market scale of recombinant human coagulation factor VIII in China will continue to increase from 2018 to 2022. After 2022, there is possibility that Chinese companies may launch recombinant human coagulation factor VIII.

Topics Covered
Development of Recombinant Human Coagulation Factor VIII in China
Sales of Recombinant Human Coagulation Factor VIII in China
Sale price of Recombinant Human Coagulation Factor VIII in the Chinese market
Manufacturers of Recombinant Human Coagulation Factor VIII in the Chinese market
Research progress of Chinese companies on Recombinant Human Coagulation Factor VIII
Chinese market prospects on Recombinant Human Coagulation Factor VIII from 2018 to 2022

The post Investigation Report on Recombinant Human Coagulation Factor VIII in China, 2018-2022 first appeared on CRI Report.

Investigation Report on China Budesonide Market, 2018-2022

admin — Fri, 17 Aug 2018 09:04:44 +0000

Description
Every year, nearly 300 million people in China, including over 50 million cough patients, get infected with respiratory diseases. It is estimated that the number of asthma patients in China has exceeded 20 million. Inhaled corticosteroids are suitable for the long-term treatment of bronchial asthma and can avoid all kinds of adverse reactions caused by systemic use of corticosteroids. At present, the main inhaled corticosteroids used in clinical practice are Budesonide, Fluticasone and Beclomethasone.
In the 1990s, Budesonide was successfully developed by AstraZeneca to be used for the treatment of non-corticosteroid dependent or corticosteroid-dependent bronchial asthma and chronic obstructive pulmonary disease. In Jun. 1997, Budesonide aerosol was approved by the FDA.
In 1994, China approved the import of Budesonide. In 1995, Astra (Wuxi) Pharmaceutical was approved to manufacture and sell Budesonide in China. Budesonide has been developing rapidly since it entered the Chinese market. Its annual sales increased from approximately CNY 100 million in 2007 to approximately CNY 1.2 billion in 2017 with the CAGR from 2007 to 2017 up to 27.7%. There is a high demand for Budesonide in China. The majority of Budesonide currently sold on the market are manufactured by AstraZeneca, Synmosa Biopharma Corporation, Lunan Better Pharmaceutical Co., Ltd., Orion Pharma and Shanghai Sine Pharmaceutical Laboratories Co., Ltd. In terms of sales, AstraZeneca has the highest market share, accounting for more than 90% of the Chinese market in 2017.
Owing to the aggravating environmental pollution and ageing population, China will see a rising incidence of respiratory diseases from 2018 to 2012, which will lead to an ever-expanding Budesonide market.

Topics Covered
-Development history of Budesonide in China
-Size of Chinese Budesonide market
-Market share of major Budesonide manufacturers in China
-Market share of various dosage forms of Budesonide in China
-Budesonide prices on the Chinese market
-Prospects of Chinese Budesonide Market, 2018-2022

The post Investigation Report on China Budesonide Market, 2018-2022 first appeared on CRI Report.